东宝生物
(300239)
| 流通市值：29.37亿 | | | 总市值：29.56亿 |
| 流通股本：5.90亿 | | | 总股本：5.94亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 622,608,106.36 | 414,692,385.37 | 190,525,037.37 | 745,307,726.02 |
| 营业收入 | 622,608,106.36 | 414,692,385.37 | 190,525,037.37 | 745,307,726.02 |
| 二、营业总成本 | 567,526,960.73 | 375,655,075.35 | 168,542,826.28 | 679,496,993.61 |
| 营业成本 | 481,944,230.99 | 323,126,889.12 | 144,255,143.98 | 571,236,707.7 |
| 税金及附加 | 9,949,447.66 | 6,560,326.84 | 2,793,272.19 | 11,319,719.73 |
| 销售费用 | 14,905,523.86 | 9,840,988.49 | 4,877,689.22 | 19,025,129.39 |
| 管理费用 | 36,340,565.3 | 24,513,681.37 | 10,970,426.91 | 51,175,787.99 |
| 研发费用 | 20,121,617.85 | 10,849,336.15 | 5,268,894.44 | 25,481,838.96 |
| 财务费用 | 4,265,575.07 | 763,853.38 | 377,399.54 | 1,257,809.84 |
| 其中:利息费用 | 6,294,844.17 | 1,716,014.93 | 855,955.03 | 4,011,729.68 |
| 其中:利息收入 | 2,672,431.96 | 1,361,269.46 | 644,074.1 | 2,775,997.22 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -1,206,907.89 | -969,650.52 | -650,492.84 | -2,861,860.37 |
| 资产处置收益 | 29,330.13 | 26,502.49 | 26,172.58 | -93,367.15 |
| 资产减值损失(新) | -4,226,861.43 | -2,943,770.1 | -2,381,654.83 | -15,126,490.31 |
| 信用减值损失(新) | 1,357,960.42 | 1,303,076.35 | 580,869.45 | -876,562.79 |
| 其他收益 | 9,133,464.47 | 5,284,057.16 | 3,028,983.63 | 12,848,944.23 |
| 四、营业利润 | 60,168,131.33 | 41,737,525.4 | 22,586,089.08 | 59,701,396.02 |
| 加:营业外收入 | 606,149.8 | 532,623.7 | 522,480 | 3,064,518.06 |
| 减:营业外支出 | 65,802.88 | 20,150.99 | 868.7 | 846,118.92 |
| 五、利润总额 | 60,708,478.25 | 42,249,998.11 | 23,107,700.38 | 61,919,795.16 |
| 减:所得税费用 | 5,767,690.04 | 4,845,973.68 | 3,413,627.17 | 7,584,386.18 |
| 六、净利润 | 54,940,788.21 | 37,404,024.43 | 19,694,073.21 | 54,335,408.98 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 54,940,788.21 | 37,404,024.43 | 19,694,073.21 | 54,335,408.98 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 54,940,788.21 | 37,404,024.43 | 19,694,073.21 | 54,337,306.91 |
| 少数股东损益 | - | - | - | -1,897.93 |
| 扣除非经常损益后的净利润 | 48,362,885.01 | 33,601,447.61 | 17,298,974.15 | 44,161,488.26 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.09 | 0.06 | 0.03 | 0.09 |
| (二)稀释每股收益 | 0.09 | 0.06 | 0.03 | 0.09 |
| 九、综合收益总额 | 54,940,788.21 | 37,404,024.43 | 19,694,073.21 | 54,335,408.98 |
| 归属于母公司股东的综合收益总额 | 54,940,788.21 | 37,404,024.43 | 19,694,073.21 | 54,337,306.91 |
| 归属于少数股东的综合收益总额 | - | - | - | -1,897.93 |
| 公告日期 | 2026-10-24 | 2026-08-24 | 2026-04-24 | 2026-03-30 |
| 审计意见(境内) | | | | 标准无保留意见 |